Mesoblast Ltd ADR MESO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $17.86
- Day Range
- $16.33–17.05
- 52-Week Range
- $11.87–21.50
- Bid/Ask
- $16.86 / $16.99
- Shares Outstanding
- 129.51M
- Market Cap
- $2.18B
- Volume/Avg
- 61,913 / 204,977
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 35.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 81
- Website
- https://www.mesoblast.com
Valuation
|
Metric
|
MESO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.00 |
Price/Sales | 35.04 |
Price/Cash Flow | — |
Price/Earnings
MESO
Financial Strength
|
Metric
|
MESO
|
|---|---|
Quick Ratio | 1.35 |
Current Ratio | 1.58 |
Interest Coverage | −3.45 |
Quick Ratio
MESO
Profitability
|
Metric
|
MESO
|
|---|---|
Return on Assets (Normalized) | −12.50% |
Return on Equity (Normalized) | −16.99% |
Return on Invested Capital (Normalized) | −12.00% |
Return on Assets
MESO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|YRpzyR | LOCK|Q>C# | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|d?vk%$ | LOCK|gg^l% | $70B | |||
| argenx SE ADR
ARGX
| LOCK|FrBy$M | LOCK|L@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?BJ@j! | LOCK|Fk$Q | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|LPbPC>@ | LOCK|Y$> | $37B | |||
| Moderna Inc
MRNA
| LOCK|!wpL!> | LOCK|&&# | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<V#m?%D | LOCK|SbS# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|D?w!%T | LOCK|!Q | $23B | |||
| Incyte Corp
INCY
| LOCK|@rgnY! | LOCK|R?@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|>&h&&mY | LOCK|H@R | $16B |
United States